Horizon Therapeutics Public Limited Company
Symbol: HZNP
NASDAQ
116.3
USDDzisiejsza cena rynkowa
62.1155
Wskaźnik P/E
0.5721
Wskaźnik PEG
26.63B
Kapitalizacja MRK
- 0.00%
Rentowność DIV
Horizon Therapeutics Public Limited Company (HZNP) Sprawozdania finansowe
Bilans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 9289.14 | 2352.8 | 1580.3 | 2079.9 | |||||||||||||||
balance-sheet.row.short-term-investments | 114.75 | 28.2 | 26.5 | 18.4 | |||||||||||||||
balance-sheet.row.net-receivables | 2670.21 | 676.3 | 632.8 | 659.7 | |||||||||||||||
balance-sheet.row.inventory | 694.64 | 169.6 | 225.7 | 75.3 | |||||||||||||||
balance-sheet.row.other-current-assets | 1549.86 | 449.3 | 360.9 | 255.5 | |||||||||||||||
balance-sheet.row.total-current-assets | 14589.66 | 3652.8 | 2799.8 | 3070.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1376.4 | 340.5 | 292.3 | 189 | |||||||||||||||
balance-sheet.row.goodwill | 4042.15 | 1010.5 | 1066.7 | 413.7 | |||||||||||||||
balance-sheet.row.intangible-assets | 13725.2 | 3474.8 | 3840.1 | 1783 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 17767.35 | 4485.3 | 4906.8 | 2196.6 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.tax-assets | 1842.66 | 431.8 | 538.1 | 560.8 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 858.6 | 204.1 | 140.7 | 55.7 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 21845.01 | 5461.8 | 5878 | 3002.2 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 36434.67 | 9114.6 | 8677.7 | 6072.6 | |||||||||||||||
balance-sheet.row.account-payables | 350.07 | 155.8 | 30.1 | 37.7 | |||||||||||||||
balance-sheet.row.short-term-debt | 64 | 16 | 16 | 0 | |||||||||||||||
balance-sheet.row.tax-payables | 172.07 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 10181.67 | 2546.8 | 2555.2 | 1003.4 | |||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1263.5 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 3198.24 | 777.3 | 840.4 | 838 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 12309.97 | 3093.3 | 3118.8 | 1171.5 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-liab | 15922.29 | 4042.4 | 4005.3 | 2047.3 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0.09 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.retained-earnings | 2612.75 | 590 | 318.6 | -215.9 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 48.28 | 12.5 | -15 | -0.1 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 17851.26 | 4469.6 | 4368.8 | 4241.4 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 20512.38 | 5072.2 | 4672.4 | 4025.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 36434.67 | 9114.6 | 8677.7 | 6072.6 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-equity | 20512.38 | 5072.2 | 4672.4 | 4025.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 36434.67 | - | - | - | |||||||||||||||
Total Investments | 114.75 | 28.2 | 26.5 | 18.4 | |||||||||||||||
balance-sheet.row.total-debt | 10245.67 | 2562.8 | 2571.2 | 1003.4 | |||||||||||||||
balance-sheet.row.net-debt | 986.05 | 210 | 990.9 | -1076.5 |
Rachunek przepływów pieniężnych
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 438 | 521.5 | 534.5 | 389.8 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 389 | 390.4 | 353.8 | 279.5 | |||||||||||||||
cash-flows.row.deferred-income-tax | -39.11 | 49.8 | -101 | -33.5 | |||||||||||||||
cash-flows.row.stock-based-compensation | 208.04 | 182.1 | 219.1 | 146.6 | |||||||||||||||
cash-flows.row.change-in-working-capital | -5.32 | -12 | -61.7 | -345.7 | |||||||||||||||
cash-flows.row.account-receivables | -44.08 | -43.5 | 34.8 | -251.2 | |||||||||||||||
cash-flows.row.inventory | 33.32 | 56.1 | 1.3 | -21.5 | |||||||||||||||
cash-flows.row.account-payables | 63.98 | 122.2 | -12.2 | 16 | |||||||||||||||
cash-flows.row.other-working-capital | -58.54 | -146.9 | -85.6 | -89.1 | |||||||||||||||
cash-flows.row.other-non-cash-items | 50.03 | 126 | 90.7 | 118.9 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1040.64 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -134.52 | -126.3 | -126.2 | -199.9 | |||||||||||||||
cash-flows.row.acquisitions-net | 28.45 | -3.1 | -2845.3 | -262.3 | |||||||||||||||
cash-flows.row.purchases-of-investments | -8.57 | -9.2 | -24.7 | -13.3 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0.22 | 4.6 | -49.6 | -30 | |||||||||||||||
cash-flows.row.other-investing-activites | -28.45 | 0 | 51.6 | 41.4 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -142.87 | -134 | -2994.1 | -464.1 | |||||||||||||||
cash-flows.row.debt-repayment | -16 | -16 | -12 | -1.7 | |||||||||||||||
cash-flows.row.common-stock-issued | 34.99 | 30.3 | 0 | 919.8 | |||||||||||||||
cash-flows.row.common-stock-repurchased | -250.08 | -250.1 | 0 | 0 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.other-financing-activites | -103.35 | -112.2 | 1482.1 | -13.5 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -334.43 | -348 | 1470.1 | 904.6 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 8.77 | -2.5 | -10.6 | 7.2 | |||||||||||||||
cash-flows.row.net-change-in-cash | 572.11 | 773.4 | -499.3 | 1003.4 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 9278.67 | 2357.6 | 1584.2 | 2083.5 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 8706.56 | 1584.2 | 2083.5 | 1080 | |||||||||||||||
cash-flows.row.operating-cash-flow | 1040.64 | 1257.8 | 1035.3 | 555.7 | |||||||||||||||
cash-flows.row.capital-expenditure | -134.52 | -126.3 | -126.2 | -199.9 | |||||||||||||||
cash-flows.row.free-cash-flow | 906.13 | 1131.6 | 909.1 | 355.8 |
Wiersz rachunku zysków i strat
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3644.41 | 3629 | 3226.4 | 2200.4 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 903.44 | 920.2 | 794.5 | 532.7 | |||||||||||||||
income-statement-row.row.gross-profit | 2740.97 | 2708.8 | 2431.9 | 1667.7 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 515.77 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 770.1 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0.4 | -5.6 | 1.8 | 3.4 | |||||||||||||||
income-statement-row.row.operating-expenses | 2173.34 | 1979 | 1878.4 | 1182.6 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 3076.78 | 2899.2 | 2672.9 | 1715.3 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.interest-expense | 68.68 | 83.7 | 81.1 | 59.6 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | -55.41 | -90.5 | -80.3 | -88.4 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0.4 | -5.6 | 1.8 | 3.4 | |||||||||||||||
income-statement-row.row.total-operating-expenses | -55.41 | -90.5 | -80.3 | -88.4 | |||||||||||||||
income-statement-row.row.interest-expense | 68.68 | 83.7 | 81.1 | 59.6 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 441.47 | 497.2 | 365.9 | 278 | |||||||||||||||
income-statement-row.row.ebitda-caps | 957.03 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 513.37 | 617.4 | 543.1 | 490 | |||||||||||||||
income-statement-row.row.income-before-tax | 443.86 | 526.9 | 462.8 | 401.6 | |||||||||||||||
income-statement-row.row.income-tax-expense | 5.86 | 5.5 | -71.7 | 11.8 | |||||||||||||||
income-statement-row.row.net-income | 438 | 521.5 | 534.5 | 389.8 |
Często zadawane pytania
Ile wynosi Horizon Therapeutics Public Limited Company (HZNP) aktywów ogółem?
Horizon Therapeutics Public Limited Company (HZNP) całkowite aktywa to 9114616000.000.
Jaki jest roczny przychód przedsiębiorstwa?
Roczny przychód to 1777018000.000.
Jaka jest marża zysku firmy?
Marża zysku firmy to 0.752.
Czym są wolne przepływy pieniężne firmy?
Wolne przepływy pieniężne to 3.873.
Jaka jest marża zysku netto przedsiębiorstwa?
Marża zysku netto to 0.120.
Jaki jest całkowity przychód firmy?
Całkowity przychód to 0.141.
Co to jest Horizon Therapeutics Public Limited Company (HZNP) zysk netto (dochód netto)?
Zysk netto (dochód netto) wynosi 521482000.000.
Jakie jest całkowite zadłużenie firmy?
Całkowite zadłużenie to 2562837000.000.
Ile wynoszą koszty operacyjne?
Wydatki operacyjne to 1979014000.000.
Jaka jest wartość gotówki firmy?
Środki pieniężne przedsiębiorstwa to 2464623000.000.